Loading...
Market
What will be Novocure's rank among top biotech companies by market cap by the end of 2025?
2
Resolution / Starting Odds
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Outside Top 30 • 25%
Market cap rankings from financial news outlets
Story
FDA Approves Novocure’s Optune Lua for Metastatic NSCLC After Platinum-Based Chemotherapy
Oct 15, 2024, 06:35 PM
The US FDA has approved Novocure's Optune Lua for the treatment of metastatic non-small cell lung cancer (mNSCLC). The approval allows Optune Lua to be used concurrently with PD-1/PD-L1 inhibitors or docetaxel for adult patients who have progressed on or after a platinum-based chemotherapy regimen. This decision is based on the results of the LUNAR study, which showed a statistically significant improvement in overall survival. The study was presented at ASCO in 2023. The approval is expected to positively impact Novocure's market cap. $NVCR shares are anticipated to see an uptick following the FDA approval.
View original story
Similar markets
Top 5 • 25%
Top 10 • 25%
Top 20 • 25%
Below Top 20 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Outside Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 5 • 33%
Top 10 • 33%
Below top 10 • 33%
Top 50 • 25%
Top 100 • 25%
Top 200 • 25%
Below Top 200 • 25%
Top 10 • 25%
Top 20 • 25%
Top 50 • 25%
Below Top 50 • 25%
Top 5 • 25%
Rank 6-10 • 25%
Rank 11-15 • 25%
Below 15 • 25%
Top 3 • 25%
Top 5 • 25%
Top 10 • 25%
Outside Top 10 • 25%
Top 1 • 25%
Top 2-5 • 25%
Top 6-10 • 25%
Outside top 10 • 25%
Top 3 • 25%
4th to 6th • 25%
7th to 10th • 25%
Outside top 10 • 25%
Top 1 • 25%
Top 2 • 25%
Top 3 • 25%
Below Top 3 • 25%